BSE: 500302
To view real time prices Login to your account
Already an existing customer? - Login Now!
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
Div yield:

Fundamental analysis


0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Underperformed both Sector by -28.2% and Sensex by -38.87%
MARKET CAP (Large Cap Stock)Rs 20,537 Cr
PE (TTM) -38.31
PE Ratio-38.31
Price to Book Value0.74
EV to EBIT25.60
EV to EBITDA20.77
EV to Capital Employed0.90
EV to Sales4.72
PEG Ratio0.00
Dividend Yield3.89%
ROCE (Latest)3.51%
ROE (Latest)-1.92%
NameDec 22Sep 22
Promoters (Change:-0.00) 43.48%43.48%
FIIs (Change:-0.81) 31.25%32.06%
Mutual Funds (Change:0.18) 2.07%1.89%
Insurance Companies (Change:-0.01) 5.27%5.28%
Other DIIs (Change:0.04) 0.73%0.69%
Non Institution (Change:0.60) 17.2%16.6%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000


Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

PEL News

Frequently Asked Questions

What is the Share price of PIRAMAL ENTERPRISES LTD. (PEL)?

PIRAMAL ENTERPRISES LTD. (PEL) share price as of February 3, 2023, on NSE is Rs 875.80 (NSE) and Rs 876.55 (BSE) on BSE.


Yes, You can buy PIRAMAL ENTERPRISES LTD. (PEL) shares by opening a Demat account with Angel One.

How do I buy PIRAMAL ENTERPRISES LTD. (PEL) from Angel One?

PIRAMAL ENTERPRISES LTD. (PEL) share can be brought through the following modes:
  1. Direct investment: You can buy PIRAMAL ENTERPRISES LTD. (PEL) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to PIRAMAL ENTERPRISES LTD. (PEL) shares.

In which sector do PIRAMAL ENTERPRISES LTD. (PEL) belong?


What is the record date for the demerger of Piramal Enterprise (PEL) shares?

The record date for the demerger of Piramal Enterprise (PEL) shares is 1 September 2022.

How many shares of Piramal Pharma will I get for every one share of Piramal Enterprise (PEL)?

Every shareholder of PEL will get 4 shares of Piramal Pharma against one share of PEL.

When will Piramal Pharma shares get listed?

Piramal Pharma shares will be listed on 19 October after it’s demerger from PEL.

What is the total Asset of Piramal Enterprise?

The total asset of Piramal Enterprise is Rs. 99,681 crores.

Who are the promoters of Piramal Enterprise?

Some of the promoters of Piramal Enterprise are The Sri Krishna Trust, PRL Realtors LLP, V3 Designs LLP, Piramal Welfare Trust (previously known as The Piramal Enterprise Executives Trust), AASAN Info Solutions (India) Pvt. Ltd., and The Ajay G. Piramal Foundation.

What are the Subsidiaries that comes under Piramal Enterprise?

Some of the major subsidiaries that come under Piramal Enterprise are Piramal Capital & Housing Finance Limited [previously known as Dewan Housing Finance Corporation Limited] (‘DHFL’), PHL Fininvest Private Limited, Piramal International Mauritius, Piramal Holdings (Suisse) SA, and Piramal Critical Care Italia.

About PEL

Today's live share price for PIRAMAL ENTERPRISES (PEL) LTD is NSE: ₹ 875.80, BSE: ₹ 876.55 with a current market capitalization of .

Piramal Healthcare Limited (PHL) (erstwhile Nicholas Piramal India) is a Mumbai-based pharmaceutical company incorporated as Indian Schering Limited in 26th April of the year 1947 under British Schering Ltd. It operates in the therapeutic segments of anti-bacterials, cardiovasculars, anti-diabetics, nutritional, central nervous system and gastro-intestinal. In addition, it has a presence in the OTC segment through various joint ventures and alliances. The Company's manufacturing activities are well supported by active research and development, the R&D facility called the Quest Institute of Life Sciences in Mumbai that focuses on process development. The name of the company was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd with effect from 27th September of the year 1979. The Pharmaceutical division of the company introduced a medicine called `Mono Sorbitrate' in the year 1988 for cardiac patients. With effect from 1st April of the year 1990, Gujarat Glass Ltd (GGL) was merged with the company. During the year 1991, the new formulation plant at Pithampur in Madhya Pradesh was commissioned. After a year, in 1992, the company had set-up a second formulation plant at Pithampur in Madhya Pradesh with the State-of-the-art manufacturing facilities. With effect from 2nd December of the year 1992, the name of the company was changed from `Nicholas Laboratories Ltd' to `Nicholas Piramal India Ltd.' PHL entered into a joint venture (JV) agreement with the leading manufacturers of ophthalmic products 'Allergan' of U.S.A in the year 1993 and also the company made a JV agreement with Sateliec, France in the year 1994 for dental care products. During the year 1995, PHL had entered into a scheme of arrangement with Sumitra Pharmaceutical and Chemicals Ltd (SPCL) Hyderabad. Under the scheme bulk drug division of SPCL transferred and vested in the company effective from April of the same year. The Company entered into a product tie-up with F.Hoffman-La-Roche and Boehringer Mannheim in the year 1996, both leads in Pharma research. The Flaconnage (Glass) Division of the company was successfully commissioned 5MW captive power plant at Kosamba in the same year 1996 to insulate the division from the vagaries of power availability and tariff increases. With effect from 1st April of the identical year of 1996, Boehringer Mannheim India Ltd. (BMIL) was merged with company. During the year 1997, PHL's state-of-the-art 230 TPD plant for manufacture of sodaline containers at Jambusar near Baroda was commissioned with an investment of Rs 125 crores and also in the same year the company made various agreements regarding marketing and in different disciplines. A joint venture was made with Allergan, US, for eye care products, Scholl, UK, for foot-care products, and with Cytran, US, for immunological products. The company took over Jenkins Botswana, a formulation company based in South Africa. In 1998, a memorandum of understanding (MoU) was signed with a major European chemicals company to start manufacturing speciality chemicals with equity partnership. During the same year of 1998, PHL had acquired the basic research unit of Hoechst Marion Roussel (India) at Mulund on the outskirts of Mumbai for about Rs.20 crore. During the year 1999, the company had launched nine products including Recormon, Accutrend, Amexyl, Orthrobid Gel and Carvetrend and also PHL had identified an anti-cancer molecule at its research centre. It became the first Indian pharmaceutical company to join the Industrial Liaison Programme (ILP) of Massachusetts Institute of Technology (MIT), USA. The Company made tie-up with the Centre for Biochemical Technology (CBT) in the year 2000 for conducting basic research in genomics and in the saem year PHL acquired a 40 per cent stake in Rhone-Poulenc India Ltd, which made it the second largest pharmaceutical group in India. Also entered into a research alliance with Hindustan Lever for developing Cosmoceuticals and personal care products. The Industrial Paints Division of the company would be hived off into a separate joint venture company with an international player. PHL had pulled out of its 50:50 joint venture with the UK-based Scholl Plc (now known as Seton-Scholl Healthcare Plc) in the year 2001. The group closed the acquisition of a 27.72 per cent equity stake in German Remedies Ltd. The Company had entered into a strategic alliance with MD India Healthcare Services Pvt Ltd. In the year 2002, ICI India transferred its pharmaceuticals business to the company. PHL had launched a new generation anti-allergic called 'Airitis' to combat allergic rhinitis in the country during the period of 2003. In the same year, the company dropped the Frame Co operation Agreement with F Hoffman La Roche and contradictorily signed agreement with Advanced Medical Optics for supply of products. During the year 2004, PHL had entered into research collaboration with the Bangalore-based Indian Institute of Science (IISc) to identify potential new targets for developing drugs to treat fungal infections and sealed an In-Licensing Agreement with Genzyme Corporation for Indian Market. Also in the same year of 2004, joined hands with NII for research on inflammation drugs. In the year 2005, the company had acquired Avecia Pharmaceuticals, UK. BioSyntech signed scientific collaboration agreement with the company in November of the year 2006 and also in the same year PHL had signed an agreement to acquire Pfizer's Morpeth, UK Facility with potential outsourcing revenues exceeding US. The Plant Screening Agreement was ensued between the company and Pharmaceuticals, Inc in January of the year 2007 to discover novel diabetes therapeutic agents. PHL had spun off its new chemical entity and herbal drug research division into a stand-alone company in the same year 2007. As at January 2008, PHL had signed MoU on research in oncology with Pierre Fabre Laboratories. This agreement formalises the collaboration between the two pharmaceutical laboratories specialising in research on natural substances. PHL had inked a pact for purchase of Anafortan and CEFI Brand Groups of Khandelwal Laboratories (K-Lab) for a total consideration of Rs 1,160 million in April of the year 2008. The Company completed a definitive agreement with Plasma, Germany in July of the year 2008 to acquire PlasmaSelect`s polygeline based blood plasma products marketed under the brand name `Haemaccel' in over 38 countries with the cash consideration of Euro 7.7 million for the transaction. In July 2008, the company jointly with Pierre Fabre launched a new dermo-cosmetic range, `Ducray'.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers